Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Oxaliplatin→

Oxaliplatin Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
61825-94-3
Molecular formula
C8H14N2O4Pt
Molecular weight
397.29 g/mol
Drug class
Platinum-based Drug
Mechanism of action
Physiochemical Activity
Indications / reported uses
  • Urinary Bladder Neoplasms
  • Ovarian Neoplasms
  • Testicular Neoplasms
  • Colorectal Neoplasms
View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Oxaliplatin Environmental Risk Assessment (ERA) (the Oxaliplatin ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.